sur ABIVAX (EPA:ABVX)
Abivax Announces Positive Results for Obefazimod in Ulcerative Colitis Treatment
Abivax has shared positive interim results for their open-label maintenance study of obefazimod, a treatment for moderate to severe ulcerative colitis. Patients administered a reduced 25 mg dose daily showed high rates of clinical remission after 48 and 96 weeks. At baseline, 89% of patients were in remission, with 84% maintained at week 48, and 87% at week 96.
Safety results aligned with previous studies, showing no new safety concerns. Patient retention was strong, with minimal discontinuation. These findings support obefazimod as a promising long-term therapy for ulcerative colitis.
Obefazimod's oral administration offers a convenient option, meeting a significant need in ulcerative colitis treatment. Further data will be presented at an upcoming medical meeting.
R. H.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de ABIVAX